The GLORIA study: A Phase 3, Randomized, Open-Label Study of the Anti-Globo H Vaccine Adagloxad Simolenin (OBI-822)/OBI-821 in the Adjuvant Treatment of Patients with High Risk, Early-Stage Globo H-Positive Triple Negative Breast Cancer

Project: Research

Project Details

StatusFinished
Effective start/end date9/03/23 → 8/03/25

Keywords

  • Clinical trial
  • GLORIA